Akari Therapeutics
AKTX
6 hedge funds and large institutions have $892K invested in Akari Therapeutics in 2023 Q4 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
14% less funds holding
Funds holding: 7 → 6 (-1)
25% less capital invested
Capital invested by funds: $1.19M → $892K (-$298K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OFW
Omnia Family Wealth
Aventura,
Florida
|
+$94.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$89.3K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$46.4K |
| 3 |
Renaissance Technologies
New York
|
-$23.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $512K | -$46.4K | -351 | -8% |
|
|
OFW
2
Omnia Family Wealth
Aventura,
Florida
| $273K | +$94.3K | +713 | +48% |
|
3
Cerity Partners
New York
| $73.8K | – | – | – |
|
|
4
Renaissance Technologies
New York
| $32K | -$23.8K | -180 | -41% |
|
5
Bank of America
Charlotte,
North Carolina
| $468 | – | – | – |
|
|
TC
6
Truvestments Capital
Sarasota,
Florida
| $156 | – | – | – |
|
7
Morgan Stanley
New York
| $50 | – | – | – |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $22 | – | – | – |
|
|
CPG
9
Cornerstone Planning Group
Fairfield,
New Jersey
| $16 | – | – | – |
|
|
NMC
10
NEA Management Company
Timonium,
Maryland
| – | -$89.3K | -565 | Closed |
|
AKTX Hedge Fund Activity: Q4 2023 in Review
6 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q4 2023, worth a combined $892K — down 25% from $1.19M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of AKTX and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was Omnia Family Wealth, adding an estimated $94.3K. The largest seller was NEA Management Company, exiting entirely with an estimated $89.3K sold.
- 6 institutional investors held Akari Therapeutics (AKTX) as of Q4 2023, down from 7 in Q3 2023.
- Funds reported $892K of Akari Therapeutics stock for Q4 2023, down 25% quarter-over-quarter.
- 0 funds opened new Akari Therapeutics positions in Q4 2023 and 1 closed out, a net change of -1 holder.
- The largest Akari Therapeutics buyer in Q4 2023 was Omnia Family Wealth, an estimated $94.3K added.
- The largest Akari Therapeutics seller in Q4 2023 was NEA Management Company, an estimated $89.3K sold.
Based on aggregated 13F filings for Q4 2023.